MedTrace Logo

Maximizing trEatment of Neurological Dysfunction Using INtravenous Guanfacine Study

NCT04742673 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2026-02-19

Study results available
· View outcomes & findings →

Summary

This proof-of-concept study examines whether the acute brain dysfunction that occurs in critically ill patients is improved by administration of intravenous guanfacine.

Conditions

Interventions

DRUG

Guanfacine

Patients randomized to the IV Guanfacine arm will receive intravenous guanfacine when they exhibit ICU delirium.

DRUG

Placebo

Patients randomized to the placebo arm will receive intravenous normal saline when they exhibit ICU delirium.

Sponsors & Collaborators

  • Massachusetts General Hospital

    collaborator OTHER

  • National Institute on Aging (NIA)

    collaborator NIH

  • Vanderbilt University Medical Center

    lead OTHER

Principal Investigators

  • Christopher Hughes, MD · Vanderbilt University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-04
Primary Completion
2024-03-30
Completion
2025-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04742673 on ClinicalTrials.gov